0309 GMT - Pro Medicus's proven ability to maintain a steady cadence of new contracts helps justify the imaging tech provider's premium valuation, according to its bulls at Goldman Sachs. The investment bank's analysts also see the Australia-listed company's A$24 million contract with NYU Lagone Health as evidence of the ability to upsell additional services to existing customers. They tell clients in a note that there is potential for Pro Medicus to renew or upgrade existing customers on favorable terms. GS lifts its target price 14.5% to A$221.00 and keeps a buy rating on the stock, which is up 10% at A$251.73. (stuart.condie@wsj.com)
(END) Dow Jones Newswires
November 27, 2024 22:09 ET (03:09 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.